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Abstract
Background: At the early stages of carcinogenesis, the induction of tumor specific T cell mediated immunity seems to block
the tumor growth and give protective anti-tumor immune response. However, tumor associated macrophages (TAMs)
might play an immunosuppressive role and subvert this anti tumor immunity leading to tumor progression and metastasis.
Methodology/Principal Findings: The Cu (II) complex, (chelate), copper N-(2-hydroxy acetophenone) glycinate (CuNG),
synthesized by us, has previously been shown to have a potential usefulness in immunotherapy of multiple drug resistant
cancers. The current study demonstrates that CuNG treatment of TAMs modulates their status from immunosuppressive to
proimmunogenic nature. Interestingly, these activated TAMs produced high levels of IL-12 along with low levels of IL-10
that not only allowed strong Th1 response marked by generation of high levels of IFN-c but also reduced activation induced
T cell death. Similarly, CuNG treatment of peripheral blood monocytes from chemotherapy and/or radiotherapy refractory
cancer patients also modulated their cytokine status. Most intriguingly, CuNG treated TAMs could influence reprogramming
of TGF-b producing CD4
+CD25
+ T cells toward IFN-c producing T cells.
Conclusion/Significance: Our results show the potential usefulness of CuNG in immunotherapy of drug-resistant cancers
through reprogramming of TAMs that in turn reprogram the T cells and reeducate the T helper function to elicit proper anti-
tumorogenic Th1 response leading to effective reduction in tumor growth.
Citation: Chatterjee S, Mookerjee A, Mookerjee Basu J, Chakraborty P, Ganguly A, et al. (2009) A Novel Copper Chelate Modulates Tumor Associated
Macrophages to Promote Anti-Tumor Response of T Cells. PLoS ONE 4(9): e7048. doi:10.1371/journal.pone.0007048
Editor: Benjamin Edward Rich, Harvard Institute of Medicine, United States of America
Received February 20, 2009; Accepted August 18, 2009; Published September 16, 2009
Copyright:  2009 Choudhuri et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Indian council of Medical research, New Delhi, India; WWW.icmr.nic.in Grant Number: 5/13/18/2007 NCDIII and 5/13/18/2004 NCDIII. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: soumitra01@yahoo.com
. These authors contributed equally to this work.
Introduction
Tumor cells escaping from the immune surveillance in
immunocompetent individuals reflects inadequate function of the
immune system. Induction of tumor specific T cell mediated
immunity may block the tumor growth and may give protective
anti-tumor immune response [1,2]. However strong immune
suppression in the tumor microenvironment makes the situation
more complicated [3,4]. It has been suggested that the growing
tumors produce various chemoattractants that have been impli-
cated in recruitment of monocytes in the tumor site. When
monocytes are recruited into the growing tumor site, local cytokine
milieu modulates the immunological functions of these newly
recruited monocytes and educates them towards tumor-associated
macrophages (TAMs) that are immunosuppressive in nature
[5,6,7]. TAMs promote tumor cell proliferation and metastasis
by secreting a wide range of growth and proangiogenic factors as
well as various metalloproteinases [8,9]. TAMs also possess poor
antigen presenting ability and effectively suppress the induction of
proper anti-tumor T cell response through the production of
immunosuppressive cytokines like TGF-b and IL-10 [6,10], as well
as promote induction and infiltration of CD4
+CD25
+FoxP3
+ T
cells (Treg) at the tumor site [11]. However, evidence suggested
that phenotype of TAMs can be reprogrammed and the presence
of IL-12 in its local milieu plays key role in reprogramming of their
functional cytokine profile towards proimmunogenic (IL-12
secreting) nature [12]. IL-12 also dictates the orchestration of T
cell response towards generation of protective anti tumor response
by stimulating T cells and NK cells to produce IFN- c (13, 14, 15).
Induction of IFN- c production and suppression of IL-4
production by IL-12 has been shown to induce anti-tumor
response in murine tumor models [14,16]. Thus, if TAMs possess
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e7048functional plasticity, it would be useful target for anti-tumor
therapy because skewing them again towards proimmunogenic
nature could induce proper anti tumor Th1 response that can
effectively reduce tumor growth and metastasis.
It has been reported earlier that copper homeostasis plays a vital
role in drug resistance in cancer and also found to be essential in
mediating several intracellular signals in macrophage [17,18]. An
elevated copper level in macrophage is associated with the
production of inflammatory cytokines whereas a copper deficiency
attenuates its conventional immunological functions [19]. Previ-
ously our laboratory had synthesized a novel copper chelate
[Copper N-2(hydroxy acetophenon) glycinate (CuNG)] which was
found to be a potent immunomodulator able to elevate the
number of CD4
+ IFN-c producing cells in drug resistant tumor
[Doxorubicin resistant Ehrlich Ascites Carcinoma (EAC/Dox)]
bearing mice [20,21]. In this study we found that CuNG has direct
effect on TAMs and can modulate their functional cytokine
pattern, inducing their conversion from immunosuppressive to
proimmunogenic nature. Herein we have also found that change
in regulatory cytokine profile of TAMs was able to redirect the T
helper function, reprogram Treg population and augment the
induction of protective immune response in EAC/Dox bearing
mice. Similar results were also obtained in case of peripheral blood
monocytes from chemo and/or radiotherapy refractory patients.
Results
CuNG treatment can directly modulate the regulatory
cytokine profile of Tumor Associated Macrophages
(TAMs)
Previous study with the novel copper chelate CuNG revealed its
immunomodulatory properties in EAC/Dox bearing mice. CuNG
caused augmentation of apoptogenic inflammatory cytokine
(mainly IFN-c) production and resolution of tumors [21]. This
finding prompted us to further investigate how this copper chelate
(CuNG) induces the production of such inflammatory cytokines.
First we have tried to know whether CuNG can directly act on
CD4
+ T cells [as this population is the predominant source of
inflammatory cytokines following CuNG administration (i.m) [21]]
to induce IFN-c production. It was observed that in vitro
application of CuNG did not have any significant effect in the
IFN-c production by CD4
+ T cells obtained from EAC/Dox
bearing mice (Fig. 1A). TAMs play pivotal role in suppression of
IFN-c producing CD4
+ T cells (Th1 response) at the tumor site
through establishment of immunosuppressive cytokine environ-
ment [22]. Therefore, we probed whether CuNG could modulate
the functional behavior of TAMs from suppressive to proimmu-
nogenic type so that protective Th1 response can be elicited. To
test this possibility, EAC/Dox bearing mice were treated with
CuNG (i.m, 5 mg/kg of body weight), TAMs were isolated 15
days following CuNG treatment (i.e., when tumors start to reduce
prominently) and intracellular cytokine profile was checked by
flow cytometry (Fig. 1B). It was observed that TAMs isolated from
CuNG treated group released elevated level of IL-12 compared to
the TAMs obtained from untreated EAC/Dox bearing mice
(77.36% vs. 22.6%, MFI: 71.8961.24 vs. 15.3561.42). On the
other hand, production of two major suppressive cytokines, IL-10
(63.21% vs. 94.09%, MFI: 48.6860.95 vs. 82.4460.68) and TGF-
b (19.21% vs. 70.68%, MFI: 14.7760.72 vs. 92.3560.81) was
found to be down regulated in the CuNG treated group compared
to the untreated control.
The result was further confirmed by performing ELISA for IL-
12, IL-10 and TGF-b. It was observed that 12 h and 24 h cultures
of TAMs in the presence of CuNG did not show any modulation
in regulatory cytokine production but 48 h of CuNG treatment
caused significant up regulation in IL-12 production (Fig. 1E)
(.13.5 fold) whereas the suppressive cytokine TGF-b (Fig. 1F)
production was highly (,17.2 folds) and IL-10 production (Fig. 1D)
was moderately down regulated (,3.71 folds) as compared to the
untreated control. These results together indicate that CuNG
treatment significantly modulates the production of regulatory
cytokines by TAMs.
Interestingly, it was observed that CuNG treated TAMs
maintain a sustained higher level of reactive oxygen species
(ROS; measured in terms of peroxide) till 18 h post treatment
compared to untreated TAMs (Fig. 1C). Chelation of ROS with
the anti-oxidant tocopherol (50 mM) reversed the nature of CuNG
treated TAMs by increasing IL-10 and TGF-b production and
decreasing IL-12 generation to levels comparable to untreated
TAMs (Fig. 1D, E and F).
In vivo administration of CuNG in EAC/Dox bearing mice
induce Th1 type response
It has well been documented that the cytokine IL-12 plays a
pivotal role in Th1 polarization [13,15]. Since administration (i.m)
of CuNG in EAC/Dox bearing mice induce elevated level of IL-
12 production by TAMs at the tumor microenvironment, we
therefore checked whether in vivo CuNG treatment could
modulate the cytokine profile of the tumor associated lymphocytes
(TAL) towards Th1 type. Flow cytometric analysis revealed that
CD4
+ population of TAL from CuNG treated group showed
higher percentage of IFN-c positive population compared to
untreated group (21.42% vs. 3.54%). On the contrary, the
percentage of IL-4 and TGF-b positive populations in TALs
isolated from in vivo CuNG treated animals was found to be
greatly reduced compared to that from untreated animals (7.73%
vs. 17.59% and 6.18% vs. 19.24%respectively) (Fig. 2).
Soluble factors from functionally altered TAMs can skew
unresponsive CD4
+ T cells of untreated EAC/Dox mice
towards Th1 type
The conventional role of macrophage in tumor rejection through
recognition of tumor antigen and participation in induction of anti-
tumor T cell response is changed at the tumor site where it seems to
produce elevated levels of immunosuppressive cytokines like IL-10 and
TGF-b that effectively attenuate the induction of anti tumor response.
We have shown here that single administration of CuNG in EAC/Dox
bearing mice was able to alter the functional polarization of TAMs
from immunosuppressive to proimmunogenic in nature leading to
induction of Th1 type of response at the tumor site. These observations
prompted us to investigate whether the soluble mediators derived from
CuNG treated TAMs are sufficient to redirect the tumor associated
unresponsive CD4
+ T cells towards Th1 type in the absence of contact
dependent signal. To assess this possibility TAMs were isolated from
untreated EAC/Dox bearing mice and cultured for 48 h in presence
or absence of CuNG. On the other hand TAMs from in vivo CuNG
treated mice were cultured in absence of CuNG for 48 h. Following
completion of incubation, cell free supernatants were obtained, diluted
2 folds with fresh medium and used to culture CD4
+ cell enriched
TALs. Following 96 h of incubation, cells were harvested and the levels
of different Th1 and Th2 cytokine specific mRNA expressions were
studied by semi-quantitative RT-PCR using specific primers. We
observed that CD4
+ T cell populations cultured with cell free
supernatant of either in vitro CuNG treated TAMs or TAMs from
in vivo CuNG treated animals manifested significantly elevated levels
of expression of Th1 specific cytokine mRNA (IFN-c)w h e r e a sT h 2
specific (IL-4) and suppressive (TGF-b) cytokine mRNA expression
Reprogramed TAM Changes TAL
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the contrary, IL-4 and TGF-b mRNA expressions were found to be
significantly higher in the untreated control group (Fig. 3A & B).
Similar results were obtained when Th1 and Th2 specific cytokine
production by CD4
+T cells were analyzed by flow cytometry. CD4
+T
cell population cultured with cell free supernatant derivedfrom cultures
of either in vitro CuNG treated TAMs or TAMs from in vivo CuNG
treated mice, induced augmented IFN-c production from CD4
+TALs
obtained from untreated EAC/Dox bearing mice. Flow cytometric
data (Fig. 3C) also revealed that culture supernatant obtained from in
vitro or in vivo CuNG treated TAMs highly reduced the percentage of
TGF-b and IL-4 producing CD4
+ T cells. So both mRNA expression
level and intracellular cytokine assay clearly indicate that the pattern of
functional cytokine production by a lineage committed CD4
+ T cells
can be modulated in response to its local cytokine microenvironment
created by the antigen presenting cells (like TAMs).
CuNG treated TAMs induce reprogramming of cytokine
status of CD4
+CD25
+ T cells
CD4
+CD25
+FoxP3
+ (Treg) are well known culprit for creation
of immunosuppressive tumor microenvironment via production of
high levels of TGF-b [23,24]. It has previously been shown by us
that CuNG treatment in vivo reduces CD4
+CD25
+FoxP3
+ T cells
at the tumor site (21). Since under in vitro condition combination
Figure 1. Both in vitro and in vivo CuNG treatment caused alteration of cytokines profile of TAMs. A) ELISA. B) Flow cytometry. C)
Fluorometric analysis. D, E & F) ELISA. In vitro CuNG treatment (2.5 mg/ml) did not change IFN-c production from CD4
+ T cells of TALs of untreated
EAC/Dox bearing mice (A). TAMs were purified from peritoneal ascitic fluid of both untreated and 15 days of CuNG treated EAC/Dox bearing mice and
labeled with anti F4/80 antibodies and with either intracellular IL-10 or IL-12 or TGF-b or with specific isotype control Abs. Immunofluorescence
analysis were performed by flow cytometry. Representative data of 3 independent experiments is presented (B). Purified TAMs were either kept
untreated or treated with CuNG in vitro and ROS was measured [in terms of peroxide using dichlorofluorescein diacetate (DCF-DA)] at different time
points. Results are presented as mean6SD of 3 independent experiments (C). Purified TAMs from untreated EAC/Dox bearing mice were plated
(2610
6 cells/500 ml). Cells were either kept untreated or pretreated with tocopherol (50 mM) for 1 h. Then the cells were further cultured for 12 h,
24 h and 48 h in the presence or absence of CuNG (2.5 mg/ml). The culture supernatants were collected and analyzed for cytokines IL-10 (D), IL-12 (E)
and TGF-b (F) by ELISA and results are presented as mean6SE of 3 independent experiments, each experiment having every measurement in
triplicate.
doi:10.1371/journal.pone.0007048.g001
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cytokine profile of CD4
+ TALs from TGF-b producing to IFN-c
producing, therefore we tested whether it can reprogram Treg
towards Th1 type. For this purpose sorted CD4
+CD25
+
population from TALs of untreated EAC/Dox bearing mice were
labeled with CFSE and co-cultured for 96 h with either untreated
TAMs or TAMs treated with CuNG in vitro for 48 h. T cells
cultured with untreated TAMs maintained their high TGF-b
status while cytokine status of T cells cultured with CuNG treated
TAMs was reprogrammed to low TGF-b and high IFN-c (Fig. 4A).
Furthermore, majority of the CD25
+ sorted CD4
+ cells, when
cultured with CuNG treated TAMs, lost their FoxP3 expression
vis-a `-vis decreasing TGF-b production and increasing IFN-c
generation (Fig. 4B). These cells also lose the characteristic
inhibitory property of Treg on proliferation of T cells (Fig. 4C).
Redirection of the tumor associated CD4
+ T cells towards
Th1 type can be accounted for by CuNG mediated
altered level of IL-10 and IL-12 production from TAMs
It is well evident from Fig. 1B that CuNG treatment caused
alteration in the levels of IL-10 and IL-12 production by TAMs
but did not completely abrogate the IL-10 production. This
observation made us curious to further investigate whether the
combination of low level of IL-10 and high level of IL-12 that we
obtained with TAMs after CuNG treatment would have the same
potential as IL-12 alone to make the decision for the generation of
the Th1 response. To test this hypothesis, CD4
+ TAL from
untreated EAC/Dox bearing mice were cultured in the presence
of either recombinant IL-10 (rIL-10) or IL-12 (rIL-12) alone or
with a combination of rIL-10 and rIL-12 for at least 96 h. The
doses of rIL-10 and rIL-12 applied corresponded to those obtained
from the ELISA data of IL-10 and IL-12 production by either
untreated or in vitro CuNG treated TAMs. Both mRNA
expression study (Fig. 5A & B) and intracellular cytokines
production assay (Fig. 5C) indicated that CD4
+ T cells population
cultured in the presence of 0.35 ng/ml of rIL-10 and 2.7 ng/ml of
rIL-12 showed a significant up-regulation in production of IFN-c
similar to CD4
+ TALs treated with only a single high dose of rIL-
12. On the other hand, CD4
+ TALs stimulated in the presence of
1.3 ng/ml of rIL-10 and 0.2 ng/ml of rIL-12 (amount similar to
the IL-10 and IL-12 obtained from untreated TAMs), did not
show any remarkable change in cytokine production pattern from
that we observed in case of single high dose of rIL-10 treated or
untreated control group.
Interestingly it is also evident from dot plot analysis of flow
cytometry data (Fig. 5C) that the percentage of IFN-c positive cells
among CD4
+ TALs was higher when cultured in the presence of
combination of high rIL-12 and low rIL-10 compared to the high
rIL-12 alone (54.42% vs. 36.89%). Interestingly, CuNG treated
TAMs, when fixed with paraformaldehyde could not increase
IFN-c production or decrease TGF-b generation in CD4
+ TALs.
However, when a combination of low rIL-10 and high rIL-12 was
introduced in this system, TALs were reprogrammed (Fig. 5D).
Moreover, co-culture of CuNG treated TAMs and CD4
+ TALs
did not significantly increase the level of reprogramming (Fig. 5D).
These results indicate that reprogramming of TALs strongly
depends on soluble agents (high IL-12 and low IL-10) released
from reprogrammed TAMs. However, the cause of lower
percentage of IFN-c producing TALs following rIL-12 treatment
alone compared to that following treatment with high rIL-12 and
low rIL-10 remained unanswered. To explain this differential
response we reasoned that the combination of high rIL-12 and low
rIL-10 might block the death of T cells.
Presence of small amount of IL-10 in association with IL-
12 delayed the death of Th1 population
Several reports are corroborating the fact that high level of IFN-
c produced by the Th1 population mediates its own apoptosis by
up-regulating both Fas and Fas-L expression [25,26,27,28].
Recently a differential role of IL-10 as an anti-apoptotic mediator
protecting the mouse intestinal epithelial cells from IFN-c or TNF-
a mediated apoptosis by diminishing the Fas expression has been
shown [29]. These findings prompted us to investigate whether the
presence of low level of rIL-10 in combination with high rIL-12
could prolong the Th1 response by interfering with its self-killing
mechanism. To address the issue of involvement of IL-10 in
prolonging Th1 response, we cultured CD4
+ T cells obtained from
TALs of untreated EAC/Dox bearing mice either with a single
high dose or different combination of rIL-10 and/or rIL-12 for 5
days. Cell death was quantified by means of PI/Annexin V-FITC.
It was observed that rIL-12 alone induced high levels of apoptosis
while a combination of low rIL-10 and high rIL-12 protected
CD4
+ T cells from undergoing apoptosis (Fig. 6A). This apoptotic
process was found to be associated with caspase 3 activation. An
active caspase 3 level in each experimental group was represented
by the fluorescence intensity of the cleaved fluoregenic AMC
Figure 2. TALs of EAC/Dox bearing mice showed Th1 specific
response after in vivo administration of CuNG. Flow cytometry.
EAC/Dox bearing mice (n=12) were treated with CuNG (5 mg/kg of
body weight), i.m., 7 days following inoculation and 15 days after CuNG
administration TALs were isolated from the ascitic fluid of treated and
untreated animals as nonadherent population (method described in
material and method section). From isolated TALs, CD4 vs. intracellular
IFN-c, IL-4 and TGF-b production were analyzed by flow cytometry and
significantly higher percentage of CD4 population of treated group
showed positive for IFN-c (marker for Th1 response). A representative
result is presented here for comparison.
doi:10.1371/journal.pone.0007048.g002
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Caspase 3 assay clearly indicates (Fig. 6B) that intensity of active
caspase 3 levels in the high rIL-12 treated group increased much
faster than high rIL-12 plus low rIL-10 treated group
(15.66360.57 vs. 15.10761.06 at 72 h, 21.75560.74 vs.
16.09060.61 at 96 h and 27.22360.60 vs. 18.41460.36 at
120 h respectively). Addition of cell free supernatant derived from
48 h culture of both in vitro CuNG treated TAMs (originally
isolated from untreated animals) and in vivo CuNG treated TAMs
(obtained from in vivo CuNG treated animals) in the culture of
CD4
+ TALs from untreated animals resulted in restricted increase
of caspase 3 activity (14.1660.89 at 72 h, 17.5960.46 at 96 h and
20.3660.86 at 120 h and 15.6560.46 at 72 h, 16.6460.28 at
96 h and 18.9360.53 at 120 h respectively) while neutralization of
IL-10 in corresponding sets resulted in rapid increase of caspase 3
activity (16.3360.76 at 72 h, 23.2260.94 at 96 h and 29.6560.71
Figure 3. Culture supernatant of TAMs, treated with CuNG, caused altered cytokines production by TALs. A) RT-PCR. B) Densitometric
analysis. C) Flow cytometry. CD4+ T cells were purified from TALs obtained from untreated EAC/Dox bearing mice and cultured for 96 h with cell free
supernatant of TAMs obtained from untreated EAC/Dox bearing mice that were either kept untreated for 48 h or treated with CuNG (48 h
treatement) in vitro or with cell free supernatant of TAMs (cultured for 48 h in absence of CuNG) obtained from in vivo CuNG (15 days after treatment,
i.e., when tumors start regressing prominently) treated EAC/Dox bearing mice. Cytokine profile was analyzed by semi-quantitative RT-PCR. Purified
CD4
+ population from TALs (derived from untreated EAC/Dox bearing mice) cultured without any treatment were used as untreated control. After
completion of 96 h of incubation equivalent amount of mRNA (2 mg) from TALs of each experimental group was used for RT-PCR analysis and
representative data from three independent experiment is presented (A). In all cases GAPDH was used as housekeeping gene control. Densitometry
analysis of mRNA expression of each gene transcript was expressed as a ratio of cytokine mRNA to GAPDH mRNA (B). Intracellular cytokines specific
for Th1 (IFN-c) or Th2 (IL-4) or suppressive (TGF-b) production profile in the above mentioned experimental groups were also analyzed by flow
cytometry and representative data of three independent experiments is presented here (C).
doi:10.1371/journal.pone.0007048.g003
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28.0260.49 at 120 h respectively) (Fig. 6B).
Next, to decipher the mechanism underlying IL-10 mediated
inhibition of Th1 polarized CD4
+ T cell death we studied the Fas
expression in the above population. To assess this possibility levels
of Fas expression by CD4
+ T cells of untreated EAC/Dox bearing
mice cultured either with combination of high rIL-12 and low rIL-
10 or high rIL-12 alone, were analyzed at 72 h, 96 h and 120 h. It
was evident from the Fig. 6C that initially at 72 h CD4
+ T cells
cultured in the presence of high dose of rIL-12 alone showed Fas
positive population comparable to that of CD4
+ T cells cultured
with a combination of high rIL-12 and low rIL-10. However, at
96 h and 120 h positive population for Fas expression was
significantly higher in CD4
+ T cells cultured in the presence of
high dose of rIL-12 alone. Addition of cell free supernatant either
from 48 h culture of in vitro CuNG treated TAMs or 48 h culture
of TAMs from in vivo CuNG treated animals, at a ratio of 1:1 with
fresh medium in culture of TALs obtained from untreated animals
resulted in low levels of Fas expression while neutralization of IL-
10 in corresponding sets resulted in increased Fas expression
(Fig. 6C). These data clearly indicate that presence of low level of
rIL-10 in association with high rIL-12 do not interfere with the
normal function of IL-12 in inducing Th1 response although
delayed apoptosis by diminishing Fas expression thus prolonged
the Th1 response. The ratio of rIL-10 and rIL-12 in this
combination was almost 1:8, as obtained by ELISA. So we tested
other combinations like 1:4, 1:12, 1:16 and rIL-12 only along with
this combination. It was observed that 1:4 and 1:8 were the best
Figure 4. In vitro CuNG treatment caused reprogramming of Treg. A, B & C) Flow cytometry. CD4
+CD25
+ Treg populations were purified
from TALs of untreated EAC/Dox bearing mice. (A) Treg cells were labeled with CFSE and then cultured for 96 h with cell free supernatant of TAMs
(isolated from untreated EAC/Dox bearing mice) either kept untreated or treated in vitro with CuNG for 48 h. Intracellular IFN-c and TGF-b production
was analyzed with respect to specific isotype control by flow cytometry. Representative data of three independent experiments is shown. (B) Treg
cells were cultured for 96 h with supernatant of 48 h culture of untreated or in vitro CuNG treated TAMs and fresh medium (1:1). Intracellular IFN-c
and TGF-b production versus FoxP3 expression was analyzed with respect to specific isotype control by flow cytometry. Representative data of four
independent experiments is shown. (C) Tregs (CD4
+CD25
+ cells) isolated from ascitic fluid of untreated EAC/Dox bearing mice were cultured for 96 h
in presence of cell-free supernatants from 48 h cultures of untreated or CuNG treated TAMs (culture supernatant: fresh medium being 1:1). Now,
these cells were washed and cultured with CFSE loaded CD4
+ T cells isolated from inguinal and axillary lymph nodes of normal mice (Treg and CD4
+ T
cells were taken in a proportion of 1:5) for 96 h. Fluorescence levels of CFSE were measured by flow cytometry. Proliferation of normal CD4
+ T cells
either in the presence or absence of Treg cells were also analyzed by CFSE fluorescence level. Representative data of 3 independent experiments is
presented here.
doi:10.1371/journal.pone.0007048.g004
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PLoS ONE | www.plosone.org 6 September 2009 | Volume 4 | Issue 9 | e7048Figure 5. Combination of high IL-12 and low IL-10 can skew induction of Th1 response. A) RT-PCR. B) Densitometric analysis. C, D, E & F)
Flow cytometry. CD4
+ population from TALs (obtained from untreated EAC/Dox bearing mice) was purified and challenged either with single or
combine dose of recombinant IL-12 and IL-10 and cultured for 96 h. Purified CD4
+ population from TALs derived from untreated EAC/Dox bearing
mice, cultured without any treatment was taken as untreated control. Equivalent amount of mRNA (2 mg) from each experimental group was used for
semi-quantitative RT-PCR analysis and in all cases GAPDH was used as housekeeping gene control (A). Densitometry analysis of mRNA expression of
each gene transcript was expressed as a ratio of cytokine mRNA to GAPDH mRNA (B). Intracellular cytokines specific for Th1 (IFN-c) or Th2 (IL-4) or
suppressive (TGF-b) production profile in the above mentioned experimental groups were also analyzed by flow cytometry and a representative data
is shown (C). CD4+ TALs were co-cultured with untreated TAMs or CuNG treated TAMs either unfixed or fixed with paraformaldehyde or CuNG
treated fixed TAMs along with high rIL-12 and low rIL-10. In some cases CD4+ TALs and CuNG treated unfixed TAMs were separated by transwell
insert (0.45 m Meter pore) in culture. After 96 h of culture intracellular IFN-c and TGF-b production pattern were studied by flow cytometry (D). Mean
fluorescence intensity for IFN-c (Fig. 5E) and TGF-b (Fig. 5F) production by these experimental groups were also analyzed from the flow cytometric
statistical data and represented graphically. Representative data from three independent experiments is presented.
doi:10.1371/journal.pone.0007048.g005
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analysis. C & D) Flow cytometry. Purified CD4
+ population from TALs of untreated EAC/Dox bearing mice cultured in the presence of either only rIL-12
or the combination of high rIL-12 (2.7 ng/ml) and low rIL-10 (0.35 ng/ml) or the culture supernatant of in vitro CuNG treated (48 h of CuNG
treatment) TAMs or IL-10 neutralized culture supernatant of in vitro CuNG treated (48 h of CuNG treatment) TAMs or 48 h of culture supernatant from
in vivo CuNG treated TAMs or IL-10 neutralized culture supernatant of in vivo CuNG treated TAMs, for 72 h, 96 h and 120 h. Purified CD4
+ population
without any treatment was taken as untreated control. Levels of apoptosis were estimated by PI/Annexin V-FITC staining and flow cytometry.
Representative data of 3 independent experiments is presented here (A). Purified CD4
+ population pre-treated with H2O2 for 30 mins was taken as
positive control for active caspase 3 level (Mean fluorescence intensity value of H2O2 control was 39.2560.67 that was taken as 100% for active
caspase 3 level). In each experimental group active caspase 3 levels was represented by % of H2O2 positive control. Results presented are of 4
independent experiments (B). Expression of Fas by CD4
+ population of above mentioned experimental groups were also analyzed by flow cytometry.
Cells were labeled with Abs specific for CD4 and for surface Fas or with specific isotype Abs and immunofluorescence analysis was performed.
Representative result of 4 independent experiments is presented (C). CD4
+ TALs were cultured with or without different combinations of rIL-12 and
rIL-10 in absence or presence of neutralizing antibody against IFN-c for 72 h. Fas expression was studied by flow cytometry and representative data
of 3 independent experiments is presented here (D).
doi:10.1371/journal.pone.0007048.g006
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while with 1:8, IFN-c expression was much higher than 1:4 (data
not shown). Neutralization of IFN-c yielded low levels of Fas
expression in all cases (Fig. 6D, lower panel) indicating that IL-12
mediated IFN-c generation caused Fas expression and T cell
death. Thus, IL-12 is the key factor for reprogramming CD4
+ cells
towards IFN-c producing Th1 type as well as inducing T cell
death through IFN-c production.
CuNG treatment in vitro reduces the immunosuppressive
cytokines and induces IL-12 generation in blood
monocytes of patients with metastatic cancers
Next we have tried to extrapolate our experimental data under
clinical condition to see whether CuNG can modulate peripheral
blood monocytes from patients to produce similar effect. PBMC
isolated from patients with drug-resistant metastatic cancers was
treated in vitro with CuNG. After 72 h, CD14
+ adherent
population was tested for the cytokine status. Untreated CD14
+
cells exhibited an alternative activation status marked by high
levels of TGF-b and IL10. Interestingly, following CuNG
treatment, CD14
+ cells exhibited very low levels of TGF-b,
lowered IL-10 and high levels of IL-12 (Fig. 7).
Discussion
Present study establishes a new paradigm whereby the
modulation in regulatory cytokine production pattern of tumor
associated macrophages (TAMs) by the copper chelate CuNG is
an effective strategy to remodel the local cytokines milieu in the
tumor microenvironment. This plays a pivotal role in skewing
unresponsive and suppressive CD4
+ T cell populations towards
Th1 type in EAC/Dox bearing mice.
Macrophages are the most versatile cells population and are
capable of changing their functional polarization in response to the
growth factors or cytokines being released in their microenviron-
ment [30,31]. Cytokine milieu profoundly affects the functional
polarization of the macrophages [31,32]. Several studies indicate
that tumor derived factors educate the newly recruited monocytes
towards TAMs, which become immunosuppressive in nature
[6,7]. There is a symbiotic relationship between TAMs and cancer
cells, where cancer cells attract TAMs and sustain their survival
and TAMs in turn produce various growth and proangiogenic
factors that promote tumor progression and metastasis [8,33,34] as
well as effectively thwart the induction of protective anti-tumor
response [6]. However, evidences suggest that TAMs retain
functional plasticity and could be converted to nonsuppressive and
Figure 7. Treatment of CuNG upregulates IL-12 production by adherent population of PBMC from different cancer patients sample.
Flow cytometry. PBMC from different cancer patients were isolated and only adherent population was either treated with CuNG (2.5 mg/ml) or kept
untreated for 48 hr. Cells was labeled with Abs specific for surface CD14 and intracellular IL-10 or IL-12 or TGF-b and analyzed by flow cytometry.
doi:10.1371/journal.pone.0007048.g007
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vironment [12]. Stout et al. showed that in the presence of IL-12
TAMs rapidly alter their functional phenotype from tumor-
supportive and immunosuppressive to inflammatory [12]. In our
study we have showed that a novel copper chelate, CuNG,
possesses the potential to alter the immunosuppressive phenotype
of TAMs by reprogramming its proinflammatory (IL-12) versus
immumosuppressive (IL-10 and TGF-b) cytokine production
pattern. Current study also demonstrated that both in vitro and
in vivo application of CuNG evoked a robust IL-12 and
diminished IL-10 and TGF-b production by TAMs and thereby
polarize its functional phenotype towards inflammatory.
The induction of Th1 response highly depends on the critical
level of the two regulatory cytokines, IL-10 and IL-12 [35,36]. IL-
10 inhibits important aspects of cell-mediated immunity whereas
IL-12 induces type 1 cytokine production and effective anti-tumor
cell mediated response [37,38]. IL-10 overproduction by TAMs at
the tumor site has been implicated in tumor mediated immune
suppression [39]. It has also been found that transgenic mice over
expressing IL-10 under the control of IL-2 promoter were unable
to restrict the progression of immunogenic tumor whereas
applying anti IL-10 mAbs in these mice restored the in vivo
antitumor response [40]. In addition to IL-10, high TGF-b
secretion by TAMs at the tumor microenvironment seems to play
a potent immunosuppressive role by inhibiting T cell activation,
proliferation and differentiation [11,33,39]. In contrast, IL-12,
which stimulates Th1-dominant immunity in vivo, was shown to
have strong in vivo anti-tumor activity [14,38]. In our study we
have shown that CuNG caused reduced IL-10 and TGF-b and
augmented IL-12 production by TAMs at the tumor site. Elevated
levels of IL-12 production by TAMs after CuNG treatment altered
the cytokine balance at the tumor site and established a beneficial
cytokine microenvironment that efficiently countered the immu-
nosuppressive influence as well as skewed the unresponsive CD4
+
T cells population towards Th1 type. Moreover, this reprogram-
ming effect was found to be quite independent of cell-cell contact.
Persistence of Th1 response is greatly inhibited due to self-killing
of T cells due to over production of IFN-c. This remains a major
obstacle for successful tumor immunotherapy. Addition of IL-12
results in hugely elevated levels of IFN-c [41], which limits T cell
survival [42] and shortens Th1 response. Addition of IFN-c
induces a short-lived tumorocidal effect followed by immunosup-
pression and aggressive tumor growth, limiting its use as an
immunotherapeutic agent [42]. High expression of death receptors
and caspase 3 in Th1 cells make them prone to apoptosis [25–28].
Our study demonstrates that both in vivo and in vitro CuNG
treated TAMs maintained a stable balance between IL-10 and IL-
12 production where IL-12 levels were ,8 folds higher than IL-10.
This critical balance between these two cytokines was sufficient
enough to induce Th1 response, as well as, the presence of small
amount of IL-10 limits the self killing mechanism of Th1 cells and
thereby prolonged its persistence. Moreover, CuNG treated
TAMs could modulate TGFb producing CD4
+CD25
+ T cells
toward IFNc producing T cells with concomitant decrease in the
level of FoxP3 expression, indicating that Treg can be repro-
grammed toward Th1 phenotype. Similar modulation of periph-
eral blood monocytes from chemo and/or radiotherapy refractory
cancer patients from immunosuppressive to pro-inflammatory
status could be achieved by in vitro CuNG treatment. This could
also modulate Th2 type response to Th1 response (data not
shown).
The mechanisms underlying modulation of cytokine behavior of
TAM by this copper complex is yet to be deciphered and the role
of modulation of redox status cannot be ruled out [43]. The
current study suggests that CuNG treatment induced a sustained
generation of ROS. Inhibition of this ROS with anti-oxidant
reversed the cytokine generation status of CuNG-treated TAMs
toward untreated TAMs. Ongoing studies in this direction point
towards the complex interplay between intracellular signaling
events and the increase in reduced glutathione (GSH) level in late
hour of CuNG treatment following its initial depletion (2 h) in the
context of pattern of modulation of cytokine profile in macro-
phages (our unpublished observation).
In summary, we critically evaluated the anti tumor efficacy of
the novel copper chelate (CuNG) for its potential role of
modulating TAMs and thereby inducing protective anti tumoro-
genic Th1 response. Earlier study with CuNG explored its
immunomodulatory effects especially against drug resistant tumors
[21]. Here we demonstrated that CuNG causes immune
modulation in drug resistant cancer bearing individuals by altering
functional cytokine pattern of TAMs to establish a proper immune
surveillance at the tumor site. These data indicate that CuNG may
be used clinically for immunotherapy of different types of drug
resistance cancers.
Materials and Methods
Reagents
Penicillin, Streptomycin was purchased from Sigma (USA).
Recombinant murine IL-10, IL-12, opt EIA kit for assay of murine
cytokines, anti-mouse IFN-c, IL-10, IL-4, FITC conjugated IL-12
mAb, anti-mouse TGF-b, PE conjugated TNF-a mAb and all
human reactive antibodies were purchased from BD Bioscience/
BD Pharmingen (USA). Anti CD5 and CD19, F4/80 biotin
conjugated mAb (murine) were obtained from eBioscience (USA).
The cell culture medium RPMI-1640 and FCS were purchased
from Gibco, Invitrogen (USA).
Animals and Cell lines
Swiss albino mice, obtained from National Institute of Nutrition
(Hyderabad, India) and maintained in the institute animal
facilities, were used for experimental purpose with prior approval
of the Institutional Animal Ethics committee. EAC/Dox, which is
resistant against doxorubicin, cisplatin, cyclophosphamide and
vinblastine were developed and maintained according to the
previously described methods. [44].
Treatment of Animals
EAC/Dox bearing mice were kept either untreated or treated
with a single dose of CuNG (5 mg/kg of body weight) 7 days
following peritoneal inoculation with 1610
6 EAC/Dox cells
obtained from EAC/Dox bearing mice treated with Dox (48 hrs
before acquisition of cells) [21].
Cell isolation and purification
Isolation of Tumor associated macrophages
(TAM). Total ascitic fluid was drawn and kept at standing
position in a 50 ml sterile tube for at least 2 hrs for settling down
the tumor cells and then clear fluid from the upper zone was
collected. TAMs were isolated from that clear fluid first by
negative selection with anti CD5 and anti CD19 and then by
positive selection with anti F4/80 using BD IMagnet system (BD
Bioscience) according to the manufacturer’s protocol and
resuspended in RPMI-1640 containing 10% FCS. Flow
cytometric data revealed that purity of the separated population
was .90%.
Isolation of tumor associated lymphocytes (TAL) and
purification of CD4
+ T cells from TAL. For isolation of
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ascitic fluid that remained after the tumor cells settled down was
collected and centrifuged and the pellet was resuspended in
RPMI-1640 containing 10% FBS and plated over the 90 mm
plastic tissue culture plates and kept for at least ,4 hrs at 37uC
under 5% CO2 in air to allow the attachment of adherent cells.
Nonadherent cells ( TALs, 95% lymphocytes) were subsequently
removed by aspiration, harvested by centrifugation and
resuspended in RPMI-1640 containing 10% FCS. In some cases
CD4
+ populations from TALs were purified by single positive
selection with anti CD4-DM particle (BD Biosciences) or Treg
were isolated from TAL using Treg isolation kit (BD Biosciences)
using BD IMagnet system according to the manufacturer’s
protocol.
Treatment of TAMs and assay of different cytokines
production by flow cytometry and ELISA and estimation
of ROS generation
TAMs from either treated or untreated group were incubated
with anti-F4/80-FITC or PE conjugated monoclonal antibody for
45 min at 4uC. After extensive washing, cells were then fixed, and
permeabilized and stained with anti IL-12- FITC, anti IL-10- PE
and anti TGF-b- FITC mAbs or corresponding isotype controls as
described previously [21] and analyzed by flow cytometer (FACS
calibur, BD).
TAMs from untreated EAC/Dox bearing mice were plated
(2610
6 cells/ml) in 24 wells plate in the presence or absence of
CuNG (2.5 mg/ml). Supernatants were collected after 12 h, 24 h
and 48 h and assayed in triplicate for the production of IL-10, IL-
12 and TGF-b using opt EIA kit (ELISA kit from BD Bioscience)
according to the manufacturer’s protocol.
Reactive oxygen species (ROS) generation by differentially
treated TAMs was measured using dichlorofluorescein diacetate
(DCF-DA) using standard protocol described previously [45,46].
Treatment of CD4
+ T cells and Treg of untreated EAC/Dox
bearing mice in vitro
The purified total CD4
+ population from TALs of untreated
mice were plated (2610
6 cell/ml) and cultured with or with out
CuNG (2.5 mg/ml) for 24 h, 48 h and 72 h and the supernatant
was taken and assayed in triplicate for the production of IFN-c
using optEIA kit (ELISA kit from BD Bioscience) according to the
manufacturer’s protocol. In some cases the purified total CD4
+
TAL were plated (2610
6 cell/500 ml) in presence of 500 mlo f
culture supernatant obtained after culturing TAMs derived either
from in vivo CuNG treated mice or untreated EAC/Dox bearing
mice treated in vitro with CuNG (48 h of treatment). In every case
TAMs concentration was 2610
5 cell/ml. In some cases different
doses of recombinant IL-10 and IL-12 either individually of in
combination was applied on CD4
+ T cells (2610
6 cell/ml). In
some experiments CD4
+CD25
+ cells (Treg; 1610
6 cell/ml)
isolated from tumor site of untreated EAC/Dox mice ($80%
FoxP3
+) were first labeled with CFSE (5 mM/ml) and then
cultured in AIM V medium either with culture supernatant of in
vitro CuNG (48 h of CuNG treatment) treated TAMs or
untreated TAMs. For stimulation of CD4
+ T cells anti-CD3
antibody (5 mg/ml) and anti CD-28 (1 mg/ml) antibody was also
applied in this culture medium and incubated at 37uC with
5%CO2 95%air atmosphere condition. After 96 h of incubation
non-adherent populations (90–95% lymphocytes) were collected
by centrifugation at 500 g for 10 mins for performing further
experiments. For neutralization of IL-10, 100 mg/mL neutralizing
anti-IL-10 antibody was used.
Assay of different cytokines production from CD4
+ T cells
by semi-quantitative RT-PCR and flow cytometry
For assay of different cytokines by semi quantitative RT-PCR
RNA was extracted from purified CD4
+ T cells using NucleoSpin
RNA II kit (Machery-Nagel) and reverse transcribed using
RETROscript (Ambion). Primers specific for murine TGF-b
(sense, CTTTAGGAAGGACCTGGGTT; antisense CAG-
GAGCGCACAAT-CATGTT), TNF-a (sense ATGAGCACA-
GAAAGCATGATC; antisense TACAGGCTTGTCACTCGA
ATT), IFN-c (sense CTCAAGTGGCATAGATGTGGA; anti-
sense GACCTCAAACTTGGCAATACTC), IL-4 (sense
GTCATCCTGCTCTTCTTTCTC; antisense ATGCTCTT-
TAGGCTTTCCAG), IL-10 (sense ACTACCAAAGCCA-
CAAAGCAG; antisense AAGGAGTCGGTTAGCAGTATG)
and GAPDH (sense CCCACAGTAAATTCAACGGCAC; anti-
sense CATTGGGGTTAGGAACACGGA) were used with 2 mg
of sample cDNA and amplified with Taq polymerase (Promega)
using a Thermal Cycler (Applied Biosystem). For intracellular
cytokines staining of CD4
+ population the above mentioned
staining protocol were used. In brief CD4
+ population from
different experimental groups were labeled with anti CD4 FITC
or PE and intracellular anti IFN-c FITC or anti IL-4 PE or anti
TGF-b PE and immunoflorescence analysis was performed by
using FACScaliber (BD Biosciences) with CellQuest software.
Caspase assay and Fas expression study of Th1 polarized
CD
+ T cells
Purified CD4
+ T cells from TALs of untreated EAC/Dox
bearing mice were cultured either with a single high dose of rIL-12
(2.7 ng/ml) or combination of high rIL-12 (2.7 ng/ml) and low
rIL-10 (0.35 ng/ml) or culture supernatant of in vitro CuNG (48 h
of CuNG treatment) treated TAMs or IL-10 neutralized culture
supernatant of in vitro CuNG (48 h of CuNG treatment) treated
TAMs or IL-10 neutralized culture supernatant of in vivo CuNG
(15 days of CuNG treatment) treated TAMs for 72 h, 96 h and
120 h. Purified CD4
+ population without any treatment was taken
as untreated control. 30 mins pretreatment with H2O2 (500 mM/
ml) was considered as positive control. An active caspase 3 level
was assayed by using caspase 3 assay kit (BD Pharmingen)
according to the manufacturer’s protocol using spectrofluorimeter
(Varian). In these groups CD4
+ population vs. Fas expression was
also studied by flow cytometry.
Cytokine assay of adherent population of PBMC isolated
from different cancer patients
Leftover excess of blood drawn for routine examination of cancer
patients refractory to various chemotherapeutics (certified by the
Department of Surgical Oncology and Medical Oncology, Hospital
Unit, Chittaranjan National Cancer Institute) were collected as
sample fromthe Department ofClinical Biochemistry,Hospital Unit,
Chittaranjan National Cancer Institute. Patient profile is given in
Table 1. PBMC were isolated by Histopaque
TM (Sigma). Adherent
population from PBMC was isolated and either kept untreated of
treated with CuNG (2.5 mg/ml) for 48 h. Intracellular cytokines were
assayed by above mentioned protocol, in brief, adherent cells were
scraped off from the plate and labeled with anti human CD14 FITC
and intracellular anti human IL-10 PE or anti human IL-12 PE or
anti human TGF-b PE and analysis was performed using
FACScaliber (BD Biosciences) with CellQuest software.
Statistical analysis
Each experiment was done three to five times and results were
expressed as mean6SE and Student’s t test for significance was
Reprogramed TAM Changes TAL
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show representative data of at least three independent experi-
ments.
Author Contributions
Conceived and designed the experiments: SKC SC AM JMB. Performed
the experiments: SKC SC Pc. Analyzed the data: SKC SC AM JMB Pc
AG AA. Contributed reagents/materials/analysis tools: AG AA DM SG
RB MA JB PD GS MC TD. Wrote the paper: SC AM JMB.
References
1. Van der Bruggen P, Traversari C, Chomoez P, Lurquin C, De plean E, et al.
(1991) A gene encoding an antigen recognized by cytotoxic T lymphocytes on a
human melanoma. Science 254: 1643–1647.
2. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, et al. (1998)
The central role of CD4+ T cells in the antitumor immune response. J Exp Med
188: 2357–2368.
3. Zou W (2005) Immunosuppressive networks in the tumor environment and their
therapeutic relevance. Nat Rev Cancer 5: 263–274.
4. Whiteside TL (2005) Immunology of head and neck cancer. Cancer Metastasis
Rev 24: 95–105.
5. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A (2002) Macrophage
polarization: tumor associated macrophages as a paradigm for polarized M2
mononuclear phagocytes. Trends Immunol 23: 549–555.
6. Bronte V, Serafini P, Apolloni E, Zanovello P (2001) Tumor-induced immune
dysfunctions caused by myeloid suppressor cells. J Immunother 24: 431–446.
7. Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, et al. (1996)
Association of macrophage infiltration with angiogenesis and prognosis in
invasive breast carcinoma. Cancer Res 56: 4625–4629.
8. Sunderko ¨tter C, Goebeler M, Schulze-Osthoff K, Bhardwaj R, Sorg C (1991)
Macrophage-derived angiogenesis factors. Pharmacol Ther 51: 195–216.
9. Bicknell R, Harris AL (1991) Novel growth regulatory factors and tumor
angiogenesis. Eur J Cnacer 27: 781–785.
10. Elgert KD, Alleva DG, Mullins DW (1998) Tumor-induced immune
dysfunction: the macrophage connection. J Leukocyte Biol 64: 275–290.
11. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kru ¨ger C, et al. (2008) A new
population of myeloid-derived suppressor cells in hepatocellular carcinoma
patients induces CD4(+)CD25(+)FoxP3(+) T cells. Gastroenterology 135:
234–243.
12. Watkins SK, Egilmez NK, Suttles J, Stout RD (2007) IL-12 rapidly alters the
functional profile of tumor-associated and tumor-infiltrating macrophages in
vitro and in vivo. J Immunol 178: 1357–1362.
13. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, et al. (1993)
Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper
type 1 (Th1)-specific immune responses and inhibits the development of IL-4-
producing Th cells. J Exp Med 177: 1199–1204.
14. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, et al. (1993)
Antitumor and antimetastatic activity of interleukin 12 against murine tumors.
J Exp Med 178: 1223–1230.
15. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, et al. (1993)
Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced
macrophages. Science 260: 547–549.
16. Wall L, Burke F, Barton C, Smyth J, Balkwill F (2003) IFN-c induces apoptosis
in ovarian cancer cells in vivo and in vitro. Clin Cancer Res 9: 2487–96.
17. Majumder S, Chatterjee S, Pal S, Biswas J, Efferth T, et al. (2009) The role of
copper in drug-resistant murine and human tumors. Biometals 22: 377–384.
18. Percival SS (1998) Copper and immunity. Am J Clin Nutr 67: S1064–S1068.
19. Leary Sc, Winge DR (2007) The Janus face of copper: its expanding role in
biology and the pathophysiology of disease. EMBO reports 8: 224–227.
20. Majumder S, Panda GS, Choudhuri SK (2003) Synthesis, characterization and
biological properties of a novel copper complex. Eur J Med Chem 38: 893–898.
21. Mookerjee A, Basu JM, Dutta P, Majumder J, Bhattacharya S, et al. (2006)
Overcoming drug-resistant in cancer by a newly developed copper chelate through
host protective cytokine mediated apoptosis. Clin Cancer Res 12: 4339–4349.
22. Duluc D, Corvaisier M, Blanchard S, Catala L, Descamps P, et al. (Feb 27,
2009) Interferon-gamma reverses the immunosuppressive and protumoral
properties and prevents the generation of human tumor-associated macrophag-
es. Int J Cancer. [Epub ahead of print].
23. Strauss L, Bergmam C, Szczepanski M, William G, Johnson JT, et al. (2007) A
unique subset of CD4
+CD25
+FoxP3
+ T cells secreting interleukin 10 and
transforming growth factor b1 mediated suppression in the tumor microenvi-
ronment. Clin Cancer Res 13: 4345–4354.
24. Mills KH (2004) Regulatory T cells: friend or foe in immunity to infection? Nat
Rev Immunol 4: 841–855.
25. Siegel RM, Chan FK, Chun HJ, Lenardo MJ (2000) The multifaceted role of Fas
signaling inimmune cell homeostasis and autoimmunity. Nat Immunol 1: 469–474.
26. Seder RA, Ahmed R (2003) Similarities and differences in CD4
+ and CD8
+
effector and memory T cell generation. Nat Immunol 4: 835–842.
27. Lu B (2006) The molecular mechanisms that control function and death of
effector CD4
+ T cells. Immunol Res 36: 275–282.
28. Lu B, Zagouras P, Fischer JE, Lu J, Li B, et al. (2004) Kinetic analysis of
genomewide gene expression reveals molecule circuitries that control T cell
activation and Th1/Th2 differentiation. Proc Natl Acad Sci 101: 3023–3028.
29. Bharhani MS, Borojevic R, Basak S, Ho E, Zhou P, et al. (2006) IL-10 protects
mouse intestinal epithelial cells from Fas-induced apoptosis via modulating Fas
expression and altering caspase-8 and FLIP expression. Am J Physiol Gastro-
intest Liver Physiol 291: G820–G829.
30. Stout RD, Suttles J (2004) Functional plasticity of macrophages: reversible
adaptation to changing microenvironments. J Leukocyte Biol 76: 509–513.
31. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, et al. (2005) Macrophages
sequentially change their functional phenotype in response to changes in micro
environmental influences. J Immunol 175: 342–349.
32. Gordon S (2003) Alternative activation of macrophages. Nat Rev Immunol 3:
23–35.
33. Pollard JW (2004) Tumor-educated macrophages promote tumor progression
and metastasis. Nat Rev Cancer 4: 71–77.
34. Lin EY, Pollard JW (2004) Macrophages: modulators of breast cancer
progression. Novartis Found Symp 256: 158–168.
35. Murphy KM, Reiner SL (2002) The lineage decision of helper T cells. Nat Rev
Immunol 2: 933–944.
36. Mosmann TR, Sad S (1996) The expanding universe of T cell subsets: Th1, Th2
and more. Immunol Today 17: 138–146.
37. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, et al. (1991) IL-
10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.
J Immunol 146: 3444–3451.
38. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, et al.
(1994) Recombinant IL-12 administration induces tumor regression in
association with IFN-c production. J Immunol 153: 1697–1706.
39. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, et al. (1995) IL-10
production in cutaneous basal and squamous cell carcinomas: a mechanism for
evading the local T cell immune response. J Immunol 155: 2240–2247.
40. Hagenbaugh A, Sharma S, Dubinett S, Wei SH, Aranda R, et al. (1997) Altered
immune response in IL-10 transgenic mice. J Exp Med 185: 2101–2110.
41. Kusaba H, Ghosh P, Derin R, Buchholz M, Sasaki C, et al. (2005) Interleukin-
12-induced interferon-gamma production by human peripheral blood T cells is
regulated by mammalian target of rapamycin (mTOR). J Biol Chem 280:
1037–1043.
42. Refaeli Y, Van Parijs L, Alexander SI, Abbas AK (2002) Interferon gamma is
required for activation-induced death of T lymphocytes. J Exp Med 196:
999–1005.
43. Murata Y, Shimamura T, Hamuro J (2002) The polarization of Th1/Th2
balance is dependent on the intracellular thiol redox status of macrophage due to
the distinctive cytokine production. International Immunology 14: 201–212.
44. Choudhuri SK, Chatterjee A (1998) Reversal of resistance against doxorubicin
by a newly developed compound, oxalyl bis (N-phenyl) hydroxamic acid in vitro.
Anticancer Drugs 9: 825–832.
Table 1. Patient profiles.
Patient Age (years) Sex Tumor type Remarks
1 66 F CA breast Brain metastasis; unresponsive to radiotherapy, 5-FU and anthracyclin (Epirubicin).
2 50 M CA lung Adrenal metastasis; unresponsive to Pacitaxel, cisplatin and radiotherapy.
3 35 F CA rectum Liver metastasis; unresponsive to 5-FU and radiotherapy.
4 45 M CA cheek Unresponsive to cisplatin, bleomycin and MTX.
doi:10.1371/journal.pone.0007048.t001
Reprogramed TAM Changes TAL
PLoS ONE | www.plosone.org 12 September 2009 | Volume 4 | Issue 9 | e704845. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Sen P, et al. (2006) Sodium
antimony gluconate induces generation of reactive oxygen species and nitric
oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase
activation in Leishmania donovani-infected macrophages. Antimicrob Agents
Chemother 50: 1788–97.
46. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, et al. (2008)
Inhibition of ABC transporters abolishes antimony resistance in Leishmania
Infection. Antimicrob Agents Chemother 53: 1080–1093.
Reprogramed TAM Changes TAL
PLoS ONE | www.plosone.org 13 September 2009 | Volume 4 | Issue 9 | e7048